The world’s best-performing stock is turning into a cautionary tale for investors chasing outsized returns from the AI boom. A mix of online hype, a tiny free float and India’s swelling base of retail ...

BSE has imposed new surveillance measures on nine stocks, including RRP Semiconductors, which has recently been in the news for its unusual price run. In a circular issued on Friday, BSE stated: “In ...

The Bombay Stock Exchange (BSE) has issued a warning to investors about RRP Semiconductor Ltd after the company’s stock rose more than 12,500% in the past year amid misinformation circulating on ...

RRP Semiconductors Ltd’s stock has risen sharply from Rs 15 in April 2024 to Rs 9,292.20 in October 2025, prompting the Bombay Stock Exchange to place it under enhanced surveillance and warn investors ...

RRP Semiconductor on October 14 clarified former cricketer Sachin Tendulkar hasn't subscribed to any of its shares and is not its brand ambassador. The clarification comes in wake of "unprecedented ...

​RRP Semiconductor Ltd, whose shares surged more than 150 times in just over a year and propelled its market valuation to nearly $1.3 billion, said Tuesday former cricketer Sachin Tendulkar is ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Sachin Tendulkar-backed RRP Electronics has secured 100 acres in Navi Mumbai relocating a semiconductor fab from one of the world’s most established semiconductor companies in Sherman, Texas. Chief ...

Tumors caused by recurrent respiratory papillomatosis are benign, but that doesn’t mean they are not serious. In this rare disease, growths form in the respiratory tract that restrict a patient’s ...

The U.S. Food and Drug Administration has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). Papzimeos is a nonreplicating, ...

Aug 15 (Reuters) - Precigen's (PGEN.O), opens new tab immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for the condition, which typically ...